Biomarin Pharmaceutical (BMRN) Equity Income (2009 - 2021)
Biomarin Pharmaceutical (BMRN) recorded quarterly Equity Income of $177000.0 in Q3 2021, up 201.14% on a QoQ basis from -$175000.0 in Q2 2021, and up 119.22% year-over-year from $80741.5 in Q3 2020.
Biomarin Pharmaceutical (BMRN) Equity Income (2009 - 2021) Analysis & Trends
Biomarin Pharmaceutical has disclosed Equity Income across 13 years of filings, most recently posting $177000.0 for Q3 2021.
- Quarterly Equity Income rose 119.22% year-over-year to $177000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was -$278000.0 (up 68.55% YoY) and the FY2020 annual result came in at -$6000.0, up 98.98% from the prior year.
- Equity Income rose to $177000.0 in Q3 2021, from -$175000.0 in the prior quarter.
- Over five years, Equity Income peaked at $1.1 million in Q4 2020 and troughed at -$1.4 million in Q1 2021.
- A 5-year average of -$199263.2 and a median of -$175000.0 in 2021 frame the typical range for Equity Income.
- Annual changes were most pronounced in 2019 — Equity Income jumped 519.57% — and 2021, when it plunged 1654.55%.
- Tracing BMRN's Equity Income over 5 years: stood at -$295000.0 in 2017, then surged by 84.41% to -$46000.0 in 2018, then soared by 519.57% to $193000.0 in 2019, then surged by 454.92% to $1.1 million in 2020, then slumped by 83.47% to $177000.0 in 2021.
- Business Quant data shows BMRN's Equity Income at $177000.0 in Q3 2021, -$175000.0 in Q2 2021, and -$1.4 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 10.52 Bn | 8.29 Bn | 571.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 177,000.00 |
| Jun 30, 2021 | -175,000.00 |
| Mar 31, 2021 | -1.35 Mn |
| Dec 31, 2020 | 1.07 Mn |
| Sep 30, 2020 | -921,000.00 |
| Jun 30, 2020 | -79,000.00 |
| Mar 31, 2020 | -77,000.00 |
| Dec 31, 2019 | 193,000.00 |
| Sep 30, 2019 | -551,000.00 |
| Jun 30, 2019 | -44,000.00 |
| Mar 31, 2019 | -185,000.00 |
| Dec 31, 2018 | -46,000.00 |
| Sep 30, 2018 | -468,000.00 |
| Jun 30, 2018 | -107,000.00 |
| Mar 31, 2018 | 68,000.00 |
| Dec 31, 2017 | -295,000.00 |
| Sep 30, 2017 | -253,000.00 |
| Jun 30, 2017 | -220,000.00 |
| Mar 31, 2017 | -523,000.00 |
| Dec 31, 2016 | -164,000.00 |